Zika Virus 1 Year Later: Lessons Learned

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Wednesday, March 8, 2017 - On-Demand Available
Master Program Number: 116 (see program format numbers below under Registration)

Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: Physicians, Scientists, Technologists, Laboratory Staff, Medical Directors, Students/Fellows, Residents, Hospital Blood Banks, Immunohematology Reference Labs (IRL’s)
Teaching Level: Intermediate

Director/Moderator: Isabella Martin, MD, Transfusion Medicine Fellow, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Speakers: Susan Stramer, PhD, Vice President, Scientific Affairs, Biomedical Services, American Red Cross; Michael Busch, MD, PhD, Senior Vice President, Research and Scientific Affairs / Professor of Laboratory Medicine, Blood Systems, Inc. / University of California, San Francisco, Scottsdale, AZ

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Discuss the impact of Zika virus on the United States blood supply.
  • Describe the assays available for Zika virus testing.
  • Identify the challenges of implementing Zika virus testing in a large blood center.

Program Description

Concern about the spread of this arbovirus and its clinical consequences have become a great concern, with the FDA issuing a guidance recommendation in August, 2016 for universal testing of donated whole blood and blood components. This program will provide an update on Zika virus, describing its impact on the US blood supply over 6 months after the FDA’s guidance, reviewing options available for testing blood products and highlighting the challenges of implementing Zika virus testing in a large blood center.


   Program #
Single Viewer: On-Demand Register17EL-4035-116
Group Viewing: On-Demand Register17EL-8035-116

Speaker Biographies

Susan L. Stramer, PhD is currently the Vice President of Scientific Affairs in Biomedical Services at the American Red Cross where she has been for the past 21 years. Her primary interests are infectious diseases of blood, their epidemiology and interventions. She has authored over 150 peer-reviewed papers and received numerous awards including those from the Red Cross, the AABB, the Centers for Disease Control and Prevention, and the National Institutes of Health. She is a past president of the AABB and currently she is the chair of the Transfusion Transmitted Diseases Committee of the AABB.

Michael P. Busch, MD, PhD, is one of the world’s leading transfusion medicine scientists. He publishes prolifically, and is well-known for his innovative and productive research. Dr. Busch is an acknowledged national leader in laboratory issues as they apply to transfusion-transmitted diseases. He has advanced the general knowledge of viral dynamics and virus-host interactions, and has been instrumental in bringing nucleic acid technology (NAT) to practical application.